Marc Iskowitz is the Executive Editor for MM+M, a publication focused on healthcare marketing and communications. With his work featured in Campaign US and PRWeek, Marc covers a wide range of topics in the pharmaceutical industry, including drug development, healthcare policy, and marketing trends.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Marc Iskowitz focuses on the healthcare and pharmaceutical industry, with a predominant emphasis on press releases and cited data. His articles cover various aspects such as drug launches, healthcare marketing, surveys, and drug pricing.
Given his focus on press releases and cited data, Marc would likely be interested in pitches that provide access to exclusive or significant data related to the pharmaceutical industry. Additionally, he may welcome expert insights into new drug launches or trends in healthcare marketing based on credible sources within the industry.
Although Marc's geographic focus is not specified, his coverage appears to have a broader international perspective. Therefore, relevant information from any location can potentially pique his interest if it aligns with his areas of coverage within the healthcare and pharmaceutical sector.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Marc Iskowitz
Here's why silver-haired Internet celebs might soon be making rounds on the Alzheimer's drug marketing scene.
There's a nettlesome gap between big-picture commercial strategy and front-line sales. Marketers say it's not likely to be bridged anytime soon.
By: Marc Iskowitz
Influencers are becoming a bigger part of pharmaceutical companies' marketing mix, and not just for helping firms gain a better understanding of their audiences.
This marks the fourth acquisition for Relevate, which plans to leverage games to round out its omnichannel life sciences offering.
It's more than just drugmakers' exorbitant prices. Experts say hospitals and patients both play a role.
By: Marc Iskowitz
Among biopharma firms, size didn't always correlate with the highest wages, a recently debuted analysis of ‘best' pharma workplaces shows.
The second annual MM+M/Publicis Health Pharma Marketing Transformation Survey shows innovation is beginning to take hold, although pharma still has a long way to go to digitally enable the marketing function.
By: Marc Iskowitz
The second annual survey shows pharma is making progress, but still has a long way to go to digitally enable the marketing function.
The dual challenges have spurred the industry to rethink its traditional comms and marketing priorities, a recent survey finds.
Set to become compulsory Nov. 20, the regulation isn't likely to make pharma ads easier for consumers to comprehend, but should aid in drugmakers' ability to meet the fair-balance standard.
(833) 317-6278 
